Vyome Holdings Inc (HIND)

$2.25 -0.12 (-5.06%)
Market Cap 12.70M
Revenue (ttm) 8.01M
Net Income (ttm) -7.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89.01%
Debt to Equity Ratio 0.00
Volume 30,000
Avg Vol 1,055,772
Day's Range N/A - N/A
Shares Out 5.64M
Stochastic %K 0%
Beta 1.34
Analysts Strong Sell
Price Target $15.00

Company Profile

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 973-832-8147
Address:
Harvard Square, One Mifflin Place Suite 400, Cambridge, United States
TheGoodestBoy
TheGoodestBoy Mar. 15 at 4:13 PM
$HIND
0 · Reply
Whathehelly
Whathehelly Mar. 14 at 4:13 PM
$HIND
0 · Reply
JasonBrunson
JasonBrunson Mar. 13 at 4:13 PM
$HIND
0 · Reply
Mother_Nature
Mother_Nature Mar. 12 at 4:13 PM
$HIND
0 · Reply
JWilliams77
JWilliams77 Mar. 11 at 4:13 PM
$HIND
0 · Reply
Loweryy
Loweryy Mar. 10 at 4:13 PM
$HIND
0 · Reply
stockboy66
stockboy66 Mar. 10 at 1:54 PM
$HIND Webull is still liquidation only for trades. I wanted to average down, but they won’t let me unless I call. It’s my money let me do as I please. WTF???🤬
1 · Reply
Don_Brooks
Don_Brooks Mar. 9 at 4:13 PM
$HIND
0 · Reply
Tester87100
Tester87100 Mar. 8 at 4:12 PM
$HIND
0 · Reply
JasonBrunson
JasonBrunson Mar. 7 at 4:12 PM
$HIND
0 · Reply
Latest News on HIND
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Feb 18, 2026, 9:00 AM EST - 25 days ago

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Feb 11, 2026, 7:00 AM EST - 4 weeks ago

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Feb 2, 2026, 7:00 AM EST - 6 weeks ago

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Jan 27, 2026, 8:00 AM EST - 6 weeks ago

Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Dec 22, 2025, 8:00 AM EST - 3 months ago

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Dec 8, 2025, 8:00 AM EST - 3 months ago

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Nov 25, 2025, 7:00 AM EST - 3 months ago

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Nov 18, 2025, 7:00 AM EST - 4 months ago

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

Nov 5, 2025, 10:13 AM EST - 4 months ago

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

RSLS

Vyome Holdings Announces Results of Annual Shareholder Meeting

Nov 4, 2025, 9:04 AM EST - 4 months ago

Vyome Holdings Announces Results of Annual Shareholder Meeting

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Sep 29, 2025, 7:00 AM EDT - 6 months ago

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Sep 17, 2025, 7:00 AM EDT - 6 months ago

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Sep 9, 2025, 8:30 AM EDT - 6 months ago

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Sep 4, 2025, 8:30 AM EDT - 6 months ago

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Aug 21, 2025, 7:00 AM EDT - 7 months ago

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Aug 18, 2025, 8:30 AM EDT - 7 months ago

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Aug 15, 2025, 8:00 AM EDT - 7 months ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Aug 14, 2025, 7:18 PM EDT - 7 months ago

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

RSLS

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Aug 13, 2025, 11:50 AM EDT - 7 months ago

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

RSLS

Vyome Announces New Board of Directors with Deep MIT and AI Ties

Aug 12, 2025, 9:48 AM EDT - 7 months ago

Vyome Announces New Board of Directors with Deep MIT and AI Ties

RSLS

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

Aug 7, 2025, 5:01 PM EDT - 7 months ago

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

RSLS

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Jul 24, 2025, 4:39 PM EDT - 8 months ago

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

RSLS

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

Jul 22, 2025, 8:31 AM EDT - 8 months ago

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

RSLS

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Jul 21, 2025, 2:10 PM EDT - 8 months ago

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

RSLS

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

Jul 1, 2025, 8:31 AM EDT - 9 months ago

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

Jun 27, 2025, 9:01 AM EDT - 9 months ago

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

RSLS

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Jun 26, 2025, 8:31 AM EDT - 9 months ago

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

RSLS

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

Jun 25, 2025, 8:31 AM EDT - 9 months ago

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

Jun 12, 2025, 8:25 AM EDT - 9 months ago

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

RSLS

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

Jun 9, 2025, 9:00 AM EDT - 10 months ago

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

RSLS

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

Jun 3, 2025, 8:31 AM EDT - 10 months ago

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

RSLS

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

May 21, 2025, 8:31 AM EDT - 10 months ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

RSLS

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

May 12, 2025, 8:32 AM EDT - 11 months ago

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ORLA RSLS

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

May 7, 2025, 8:31 AM EDT - 11 months ago

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

RSLS

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

May 2, 2025, 8:31 AM EDT - 11 months ago

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

Apr 28, 2025, 8:31 AM EDT - 11 months ago

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Apr 21, 2025, 8:31 AM EDT - 11 months ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

Apr 10, 2025, 5:54 PM EDT - 1 year ago

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

RSLS

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

Apr 9, 2025, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

RSLS

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Apr 7, 2025, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

RSLS

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

Mar 21, 2025, 11:35 AM EDT - 1 year ago

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

RSLS

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Mar 10, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

Feb 25, 2025, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

Feb 15, 2025, 11:17 PM EST - 1 year ago

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

Feb 3, 2025, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Jan 13, 2025, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:43 PM EST - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

RSLS

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Nov 12, 2024, 4:05 PM EST - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

Nov 12, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

Nov 11, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

RSLS

TheGoodestBoy
TheGoodestBoy Mar. 15 at 4:13 PM
$HIND
0 · Reply
Whathehelly
Whathehelly Mar. 14 at 4:13 PM
$HIND
0 · Reply
JasonBrunson
JasonBrunson Mar. 13 at 4:13 PM
$HIND
0 · Reply
Mother_Nature
Mother_Nature Mar. 12 at 4:13 PM
$HIND
0 · Reply
JWilliams77
JWilliams77 Mar. 11 at 4:13 PM
$HIND
0 · Reply
Loweryy
Loweryy Mar. 10 at 4:13 PM
$HIND
0 · Reply
stockboy66
stockboy66 Mar. 10 at 1:54 PM
$HIND Webull is still liquidation only for trades. I wanted to average down, but they won’t let me unless I call. It’s my money let me do as I please. WTF???🤬
1 · Reply
Don_Brooks
Don_Brooks Mar. 9 at 4:13 PM
$HIND
0 · Reply
Tester87100
Tester87100 Mar. 8 at 4:12 PM
$HIND
0 · Reply
JasonBrunson
JasonBrunson Mar. 7 at 4:12 PM
$HIND
0 · Reply
AlQasayer
AlQasayer Mar. 7 at 6:54 AM
$HIND
0 · Reply
Crabtrees
Crabtrees Mar. 6 at 4:12 PM
$HIND
0 · Reply
mccafferyfan87
mccafferyfan87 Mar. 5 at 6:18 PM
$HIND I have been tracking this trendline for quite a while and the SP just met. You be the judge...
0 · Reply
TurningAProfit
TurningAProfit Mar. 5 at 4:12 PM
$HIND
0 · Reply
Eatmon
Eatmon Mar. 4 at 4:12 PM
$HIND
0 · Reply
Tech4lyfe
Tech4lyfe Mar. 3 at 4:12 PM
$HIND
0 · Reply
mccafferyfan87
mccafferyfan87 Mar. 2 at 9:27 PM
$HIND
0 · Reply
SamRothschild33
SamRothschild33 Mar. 2 at 8:58 PM
$HIND = SHIT --- the PTB Criminals never let shit-stocks like this run up far enough to get out with any significant gains. There are still gaps all the way down to $2 -- looks like the shitbags are getting ready to tank it again to get ready for the next r/s --- FUCK YOU!
0 · Reply
Don_Brooks
Don_Brooks Mar. 2 at 4:12 PM
$HIND
0 · Reply
MexicoCity
MexicoCity Mar. 1 at 4:12 PM
$HIND
0 · Reply
mccafferyfan87
mccafferyfan87 Feb. 28 at 12:27 AM
$HIND I really hope March treats me better than February...
0 · Reply
JasonBrunson
JasonBrunson Feb. 27 at 4:12 PM
$HIND
0 · Reply